SCHEMBL722377

SCHEMBL722377

C=CC(=O)Nc1cccc(-c2cc3nccc(Oc4cccc(Cl)c4)c3o2)c1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EGFR P00533 11/20 0.49
BTK Q06187 7/20 0.49
BLK P51451 1/20 0.45
KDR P35968 2/20 0.41
PDGFRA P16234 1/20 0.41
JAK3 P52333 1/20 0.41
MAP2K7 O14733 1/20 0.41
IGF1R P08069 1/20 0.40
MET P08581 1/20 0.40
PDGFRB P09619 1/20 0.40
KIT P10721 1/20 0.40
FGFR1 P11362 1/20 0.40
BRAF P15056 1/20 0.40
FLT1 P17948 1/20 0.40
FGFR4 P22455 1/20 0.40
FLT4 P35916 1/20 0.40
EPHB4 P54760 1/20 0.40
TEK Q02763 1/20 0.40
ITK Q08881 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL722390 0.92 BTK (0.49) EGFRBTKBLKKDRPDGFRA
SCHEMBL723785 0.91 BTK (0.56) EGFRBTKBLKJAK3
SCHEMBL722213 0.89 BTK (0.59) EGFRBTKBLKJAK3
SCHEMBL723014 0.89 EGFR (0.58) EGFRBTKJAK3MAP2K7ITK
SCHEMBL723514 0.86 EGFR (0.47) EGFRBTKBLKJAK3
SCHEMBL16817232 0.81 JAK3 (0.43) EGFRBTKJAK3FGFR4
SCHEMBL721787 0.81 TGM2 (0.52) EGFRBTKBLKKDRPDGFRA
SCHEMBL721852 0.79 BTK (0.47) EGFRBTKKDRPDGFRAJAK3
SCHEMBL721853 0.79 BTK (0.47) EGFRBTKKDRPDGFRAJAK3
SCHEMBL723264 0.78 PLCG1 (0.51) EGFRBTKJAK3MAP2K7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP claimed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP claimed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO claimed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP disclosed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO disclosed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225569-A1 FUROPYRIDINE DERIVATIVES SYK, FCGRT, SSB EGFR 1317/4885BTK 4/4885BLK 91/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.